FGP
BMRN icon

Freestone Grove Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Freestone Grove Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.8M Sell
364,194
-241,993
-40% -$13.3M 0.13% 200
2026
Q1 		$34.2M Buy
606,187
+114,285
+23% +$6.66M 0.24% 143
2025
Q4 		$29.2M Buy
491,902
+15,466
+3% +$842K 0.21% 158
2025
Q3 		$25.8M Buy
476,436
+140,923
+42% +$8.06M 0.19% 175
2025
Q2 		$18.4M Buy
+335,513
New +$19.8M 0.14% 208

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Freestone Grove Partners's BMRN Position: Q2 2026 in Review

Freestone Grove Partners reduced its BioMarin Pharmaceuticals (BMRN) stake by 40% in Q2 2026, selling an estimated $13.3M and leaving 364,194 shares worth $20.8M. The position accounts for 0.13% of the portfolio, ranked #200.

Freestone Grove Partners first reported a position in BMRN in Q2 2025 and has held it in 5 quarters since. The position peaked at $34.2M in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Freestone Grove Partners held 364,194 shares of BioMarin Pharmaceuticals worth $20.8M as of Q2 2026.
  • Freestone Grove Partners sold 241,993 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $13.3M.
  • BioMarin Pharmaceuticals made up 0.13% of Freestone Grove Partners's portfolio in Q2 2026, its #200 holding.
  • Freestone Grove Partners first reported a position in BioMarin Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Freestone Grove Partners's BioMarin Pharmaceuticals position peaked at $34.2M in Q1 2026.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.